The PREFER study was an open-label, multicentre, randomized, crossover study for dulaglutide and semaglutide injection devices among injection-naïve patients receiving oral medication for type 2 diabetes
Latest Information Update: 09 Jul 2021
At a glance
- Drugs Dulaglutide (Primary) ; Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms PREFER
- 09 Jul 2021 New trial record